Trial De-Risking: Three Sources of Noise That Quietly Sink Clinical Trials

About this session

Sponsored by Replior AB. Every day of Phase III delay costs ~$56,000, yet sponsors still lose signal to three controllable sources of noise: patient attrition, subjective endpoint variance, and unmeasured environmental exposure. This session presents a practical framework combining behavioural-science eCOA with sensor-based digital endpoints—ScratchSense for continuous itch/sleep quantification and RaySense for UV, visible, and IR exposure. Attendees will explore real-world retention outcomes, sample-size reduction strategies, and a live ScratchSense demo comparing recall-based vs. continuous itch measurement.

Speaker

• CN

  Christer Nilsson

  Replior AB

  Speaker